GleamWall
中文EN

SAEN Genenta Science S.p.A. Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1838716 · Reporting currency EUR

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY26.7%
TTM EPS YoY32.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.0%
ROA-28.0%
ROIC (approx.)-43.1%
Asset turnover—

Leverage & solvency

Liabilities / assets31.5%
Debt / equity0.00x
Current ratio14.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.05x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense2.70M4.81M
SG&A expense3.90M4.95M
Operating income-6.60M-9.76M
Pretax income-6.53M-8.91M
Net income-6.53M-8.91M
EBITDA-6.58M-9.72M
EPS (diluted)-0.33-0.49
Weighted avg. shares (diluted)19.71M18.27M
Balance sheet
Cash & equivalents5.53M4.58M
Short-term investments22.62M8.08M
Current assets29.98M14.47M
PP&E, net22,46542,922
Total assets31.89M14.82M
Current liabilities2.12M2.10M
Total liabilities10.05M2.33M
Shareholders' equity21.84M12.50M
Shares outstanding23.43M18.29M
Cash flow statement
Operating cash flow-6.87M-6.24M
Capital expenditure7,6254,468
Free cash flow-6.88M-6.24M
Investing cash flow-14.54M6.88M
Financing cash flow22.29M270,885
Depreciation & amortization28,08244,523
Stock-based compensation1.01M847,255

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.